Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 49,164 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 49,164 shares of Disc Medicine stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $80.17, for a total value of $3,941,477.88. Following the transaction, the director owned 13,499 shares in the company, valued at approximately $1,082,214.83. This trade represents a 78.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Bitterman also recently made the following trade(s):

• On Thursday, September 3rd, Kevin Bitterman sold 5,203 shares of Disc Medicine stock. The shares were sold at an average price of $79.98, for a total value of $416,135.94.
• On Tuesday, September 1st, Kevin Bitterman sold 129 shares of Disc Medicine stock. The shares were sold at an average price of $79.95, for a total value of $10,313.55.

Disc Medicine Price Performance

NASDAQ:IRON opened at $79.37 on Friday. The business’s 50-day moving average price is $77.67 and its 200 day moving average price is $70.32. The firm has a market cap of $3.05 billion, a P/E ratio of -12.06 and a beta of 0.97. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.71) by $0.17. As a group, sell-side analysts predict that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on IRON shares. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Wedbush raised their price objective on Disc Medicine from $88.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday. Wall Street Zen cut Disc Medicine from a “hold” rating to a “sell” rating in a report on Saturday, August 29th. HC Wainwright upped their target price on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Disc Medicine in a research report on Tuesday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus price target of $107.70.

Institutional Investors Weigh In On Disc Medicine

Hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System grew its position in Disc Medicine by 8,273.0% during the 2nd quarter. California State Teachers Retirement System now owns 2,878,790 shares of the company’s stock worth $210,555,000 after purchasing an additional 2,844,408 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Disc Medicine in the second quarter worth $180,502,000. JPMorgan Chase & Co. grew its holdings in shares of Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after buying an additional 828,248 shares in the last quarter. BVF Inc. IL purchased a new position in shares of Disc Medicine during the fourth quarter valued at $51,616,000. Finally, Perceptive Advisors LLC acquired a new position in Disc Medicine during the fourth quarter valued at $35,794,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Key Headlines Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Wedbush raised its price target for Disc Medicine from $88 to $100 and maintained an “outperform” rating. The new target implies approximately 26% upside from the referenced $79.37 price, signaling continued analyst confidence in the company’s prospects. Benzinga analyst price target report
• Neutral Sentiment: Disc Medicine announced that management will participate in fireside chats at four upcoming investor conferences. These events could provide updates on the company’s hematology pipeline, but no new clinical or financial information was disclosed in the announcement. Disc Medicine investor conference announcement
• Negative Sentiment: Director Kevin Bitterman sold a combined 54,496 shares of Disc Medicine for approximately $4.37 million across transactions dated September 1–3. The sales reduced his position by roughly 80% overall, which may concern investors about insider conviction. However, the trades were executed under a pre-arranged Rule 10b5-1 plan, meaning they were scheduled in advance and do not necessarily reflect a current change in his outlook. SEC insider trading filing
• Negative Sentiment: Rosen Law Firm announced an investigation into potential securities claims involving allegations that Disc Medicine may have issued materially misleading business information. The announcement increases headline and litigation risk, although it does not establish wrongdoing or guarantee that a lawsuit will be filed. Rosen Law Firm investigation announcement

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.